NOXAFIL Side Effects

7028062-6 | Convulsion, Tachycardia
on Sep 23, 2010 Female patient from PERU , 13 years of age, was diagnosed with candidiasis and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, tachycardia. Noxafil dosage: .

7006477-X | Fungal Infection, Respiratory Failure, Sepsis
Patient was taking Noxafil (View Usage). Patient had the following side effects: fungal infection (What is fungal infection?), respiratory failure, sepsis (What is sepsis?) on Sep 07, 2010 from GERMANY Additional patient health information: Female patient , 64 years of age, weighting 165.3 lb, was diagnosed with prophylaxis and. Noxafil dosage: 200 Mg;tid.

7006471-9 | Gamma-glutamyltransferase Increased, Hepatic Fibrosis
Adverse event was reported on Nov 20, 2008 by a Male patient taking Noxafil (View Usage) (Dosage: ) was diagnosed with aspergillosis and. Location: GERMANY , 15 years of age, After Noxafil was administered, patient had the following side effects: gamma-glutamyltransferase increased, hepatic fibrosis.

7006439-2 | Fungal Infection, Pneumonia, Respiratory Failure, Sepsis
on Sep 07, 2010 Female patient from GERMANY , 58 years of age, weighting 189.6 lb, was diagnosed with prophylaxis and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: fungal infection (What is fungal infection?), pneumonia (What is pneumonia?), respiratory failure, sepsis (What is sepsis?). Noxafil dosage: 200 Mg;tid.


6846952-1 | Lichenoid Keratosis, Toxic Skin Eruption
on Jul 09, 2010 Male patient from FRANCE , 58 years of age, was treated with Noxafil (View Usage). Patient had the following side effects: lichenoid keratosis, toxic skin eruption. Noxafil dosage: Po. Patient was hospitalized.

6837685-6 | Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Gamma-glutamyltransferase Increased, Hepatotoxicity, Multi-organ Failure, Renal Failure, Respiratory Failure
Patient was taking Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, hepatotoxicity, multi-organ failure, renal failure, respiratory failure on Jul 01, 2010 from FRANCE Additional patient health information: Male patient , 16 years of age, was diagnosed with fungal infection (What is fungal infection?) and. Noxafil dosage: 200 Mg; Qid;. During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CYMEVAN (View Cymevan Review and Cymevan Label ), FUNGIZONE (View Fungizone Review and Fungizone Label ), AMBISOME (View Ambisome Review and Ambisome Label ), CIFLOX (View Ciflox Review and Ciflox Label ), IMIPENEM AND CILASTATIN (View Imipenem And Cilastatin Review and Imipenem And Cilastatin Label ), TARGOCID (View Targocid Review and Targocid Label ).

6791369-1 | Altered State Of Consciousness, Dyskinesia, Electroencephalogram Abnormal, Hallucination, Meningitis, Myoclonus, No Therapeutic Response, Overdose
Adverse event was reported on Jun 16, 2010 by a Male patient taking Noxafil (View Usage) (Dosage: ; Po) was diagnosed with prophylaxis, bone marrow transplant (What is bone marrow transplant?) and. Location: FRANCE , 60 years of age, Patient experienced the following unwanted or unexpected effects: altered state of consciousness, dyskinesia, electroencephalogram abnormal, hallucination, meningitis (What is meningitis?), myoclonus, no therapeutic response, overdose. During the same period patient was treated with NEORAL (0.4 Ml; Bid; Po) (View Neoral Review and Neoral Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), CELLCEPT (View Cellcept Review and Cellcept Label ), WELLVONE (View Wellvone Review and Wellvone Label ), ZELITREX (View Zelitrex Review and Zelitrex Label ), BACTRIM (View Bactrim Review and Bactrim Label ), HEMIGOXINE NATIVELLE (View Hemigoxine Nativelle Review and Hemigoxine Nativelle Label ), CORDARONE (View Cordarone Review and Cordarone Label ). Patient was hospitalized.

6754308-5 | Hypertrophy Of Tongue Papillae, Swollen Tongue, Tongue Discolouration, Tongue Disorder
on May 24, 2010 Male patient from SPAIN , 56 years of age, was diagnosed with antifungal prophylaxis and was treated with Noxafil (View Usage). Patient had the following side effects: hypertrophy of tongue papillae, swollen tongue, tongue discolouration, tongue disorder. Noxafil dosage: 400 Mg;q12h;po.

6742313-4 | Abdominal Distension, Aplasia, Bacterial Disease Carrier, Constipation, Intestinal Dilatation, Respiratory Disorder, Therapeutic Agent Toxicity, Treatment Failure
on May 17, 2010 Female patient from FRANCE , 52 years of age, was diagnosed with antifungal prophylaxis, acute leukaemia and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: abdominal distension, aplasia, bacterial disease carrier, constipation (What is constipation?), intestinal dilatation, respiratory disorder, therapeutic agent toxicity, treatment failure. Noxafil dosage: ; Po. During the same period patient was treated with ONCOVIN (6 Mg; ; Iv) (View Oncovin Review and Oncovin Label ). Patient was hospitalized.

6739038-8 | Asthenia, Fall, Feeling Drunk, Gait Disturbance, Injury, Loss Of Consciousness
Patient was taking Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, fall (What is fall?), feeling drunk, gait disturbance, injury, loss of consciousness on May 24, 2010 from UNITED STATES Additional patient health information: Female patient , 69 years of age, weighting 90.00 lb, was diagnosed with aspergillosis and. Noxafil dosage: 40 Mg -5ml- Ever 6 Hrs Po. Patient was hospitalized.

6688906-4 | Palpitations, Ventricular Extrasystoles
Adverse event was reported on Apr 09, 2010 by a Female patient taking Noxafil (View Usage) (Dosage: 600 Mg; Qd; Po) was diagnosed with acute myeloid leukaemia and. Location: FRANCE , 36 years of age, Patient had the following side effects: palpitations, ventricular extrasystoles. During the same period patient was treated with MOXIFLOXACIN HYDROCHLORIDE (400 Mg; ; Po) (View Moxifloxacin Hydrochloride Review and Moxifloxacin Hydrochloride Label ), ZOPHREN (ONDANSETRON HYDROCHLORIDE /00955302/) (; Iv) (View Zophren (ondansetron Hydrochloride /00955302/) Review and Zophren (ondansetron Hydrochloride /00955302/) Label ), CYTARABINE (; Iv) (View Cytarabine Review and Cytarabine Label ), ACUPAN (120 Mg; Qd; Iv) (View Acupan Review and Acupan Label ), AMIKIN (View Amikin Review and Amikin Label ), VANCOMYCIN HCL (View Vancomycin Hcl Review and Vancomycin Hcl Label ), BACTRIM (View Bactrim Review and Bactrim Label ), LUTENYL (View Lutenyl Review and Lutenyl Label ). Patient was hospitalized.

6659539-0 | Gastrointestinal Haemorrhage
on Mar 22, 2010 Male patient from RUSSIAN FEDERATION , child 12 years of age, was diagnosed with antifungal prophylaxis and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: gastrointestinal haemorrhage. Noxafil dosage: .

6648533-1 | Diarrhoea, Gastrointestinal Haemorrhage
on Mar 13, 2010 Male patient from RUSSIAN FEDERATION , child 12 years of age, was diagnosed with antifungal prophylaxis and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, gastrointestinal haemorrhage. Noxafil dosage: .

6593751-4 | Disease Recurrence, Squamous Cell Carcinoma
Patient was taking Noxafil (View Usage). Patient had the following side effects: disease recurrence, squamous cell carcinoma on Feb 03, 2010 from FRANCE Additional patient health information: Female patient , 59 years of age, was diagnosed with aspergillosis and. Noxafil dosage: Po. During the same period patient was treated with VFEND (Po) (View Vfend Review and Vfend Label ), CANCIDAS (View Cancidas Review and Cancidas Label ), SPORANOX (View Sporanox Review and Sporanox Label ).

6555873-3 | Bronchopneumonia, Candidiasis, Cytolytic Hepatitis
Adverse event was reported on Jan 19, 2010 by a Male patient taking Noxafil (View Usage) (Dosage: 400 Mg; Qd; Po) was diagnosed with chronic lymphocytic leukaemia and. Location: ROMANIA , 69 years of age, After Noxafil was administered, patient had the following side effects: bronchopneumonia, candidiasis, cytolytic hepatitis. During the same period patient was treated with TARGOCID (View Targocid Review and Targocid Label ), CIPRO (View Cipro Review and Cipro Label ).

6528900-7 | Blood Cholinesterase Decreased, Haemoglobin Decreased, Hepatic Function Abnormal, Metabolic Encephalopathy, Muscle Disorder, Muscular Weakness, Myoclonus, No Therapeutic Response
on Dec 16, 2009 Male patient from GERMANY , 64 years of age, weighting 216.1 lb, was diagnosed with respiratory tract infection fungal and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: blood cholinesterase decreased, haemoglobin decreased, hepatic function abnormal, metabolic encephalopathy, muscle disorder (What is muscle disorder?), muscular weakness, myoclonus, no therapeutic response. Noxafil dosage: 200 Mg; Qid; Po; 200 Mg; Qd. During the same period patient was treated with PANTOZOL /01263202/ (View Pantozol /01263202/ Review and Pantozol /01263202/ Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), SYMBICORT (View Symbicort Review and Symbicort Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ). Patient was hospitalized.

6525521-7 | Blood Cholinesterase Decreased, Haemoglobin Decreased, Hepatic Function Abnormal, Metabolic Encephalopathy, Muscular Weakness, Myoclonus, Platelet Count Decreased, Prothrombin Time Prolonged, Red Blood Cell Count Decreased
on Dec 16, 2009 Male patient from GERMANY , 64 years of age, weighting 216.1 lb, was diagnosed with fungal infection (What is fungal infection?), lung disorder and was treated with Noxafil (View Usage). Patient had the following side effects: blood cholinesterase decreased, haemoglobin decreased, hepatic function abnormal, metabolic encephalopathy, muscular weakness, myoclonus, platelet count decreased, prothrombin time prolonged, red blood cell count decreased. Noxafil dosage: 200 Mg; Qid; Po, 200 Mg; Qd;. During the same period patient was treated with PANTOZOL /01263202/ (View Pantozol /01263202/ Review and Pantozol /01263202/ Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), TAMSULOSIN /01280302/ (View Tamsulosin /01280302/ Review and Tamsulosin /01280302/ Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), SYMBICORT (View Symbicort Review and Symbicort Label ). Patient was hospitalized.

6488798-2 | Bronchopneumonia, Candidiasis, Immunosuppression
Patient was taking Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: bronchopneumonia, candidiasis, immunosuppression on Dec 02, 2009 from ROMANIA Additional patient health information: Male patient , 69 years of age, was diagnosed with chronic lymphocytic leukaemia and. Noxafil dosage: 400 Mg; Qd; Po.

6477525-0 | Gastrointestinal Haemorrhage, Melaena, Rectal Haemorrhage
Adverse event was reported on Nov 20, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: Noxafil (posaconazole) (posaconazole)) was diagnosed with skin graft and. Location: FRANCE , 52 years of age, Patient experienced the following unwanted or unexpected effects: gastrointestinal haemorrhage, melaena, rectal haemorrhage.

6431800-4 | Blood Cholinesterase Decreased, Hepatic Function Abnormal, Muscle Disorder, Muscular Weakness, Myoclonus, No Therapeutic Response, Prothrombin Time Prolonged, Status Epilepticus, Transaminases Increased
on Oct 27, 2009 Male patient from GERMANY , 64 years of age, weighting 216.1 lb, was diagnosed with fungal infection (What is fungal infection?) and was treated with Noxafil (View Usage). Patient had the following side effects: blood cholinesterase decreased, hepatic function abnormal, muscle disorder (What is muscle disorder?), muscular weakness, myoclonus, no therapeutic response, prothrombin time prolonged, status epilepticus, transaminases increased. Noxafil dosage: 200 Mg; Qid; Po, 200 Mg; Qd;. During the same period patient was treated with PANTOZOL /01263202/ (View Pantozol /01263202/ Review and Pantozol /01263202/ Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), TAMSULOSIN /01280302/ (View Tamsulosin /01280302/ Review and Tamsulosin /01280302/ Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), SYMBICORT (View Symbicort Review and Symbicort Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), FLUDARABINE /01004602/ (View Fludarabine /01004602/ Review and Fludarabine /01004602/ Label ). Patient was hospitalized.

6398337-2 | Mucosal Inflammation
on Oct 01, 2009 Female patient from SWITZERLAND , 61 years of age, was diagnosed with fungal infection (What is fungal infection?), acute lymphocytic leukaemia and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: mucosal inflammation. Noxafil dosage: 200 Mg; Tid;. During the same period patient was treated with VINCRISTINE (; Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6391179-3 |
Patient was taking Noxafil (View Usage). on Sep 30, 2009 from UNITED STATES Additional patient health information: Female patient , 66 years of age, was diagnosed with pancytopenia and. Noxafil dosage: .

6388765-3 | Escherichia Sepsis, Guillain-barre Syndrome, Neurotoxicity
Adverse event was reported on Sep 25, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: ) was diagnosed with bronchopulmonary aspergillosis and. Location: NETHERLANDS , 20 years of age, Patient had the following side effects: escherichia sepsis, guillain-barre syndrome (What is guillain-barre syndrome?), neurotoxicity. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6358620-3 | Sepsis
on Sep 09, 2009 Female patient from UNITED STATES , 32 years of age, was diagnosed with bone marrow transplant (What is bone marrow transplant?) and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: sepsis (What is sepsis?). Noxafil dosage: .

6355704-0 | Condition Aggravated
on Sep 02, 2009 Female patient from SWEDEN , 32 years of age, was diagnosed with meningitis cryptococcal and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated. Noxafil dosage: Po. During the same period patient was treated with STOCRIN (View Stocrin Review and Stocrin Label ), EPIVIR (View Epivir Review and Epivir Label ), ZERIT (View Zerit Review and Zerit Label ), AMBISOME (View Ambisome Review and Ambisome Label ).

6348328-2 | Anxiety, Depression, Pain, Pancreatitis
Patient was taking Noxafil (View Usage). Patient had the following side effects: anxiety (What is anxiety?), depression (What is depression?), pain (What is pain?), pancreatitis on Aug 19, 2009 from UNITED STATES Additional patient health information: Male patient , 31 years of age, weighting 185.0 lb, was diagnosed with fungal infection (What is fungal infection?) and. Noxafil dosage: 200 Mg;bid;po. During the same period patient was treated with CHANTIX (1 Mg;bid;po ; 1 Mg;bid;po) (View Chantix Review and Chantix Label ), LEXAPRO (View Lexapro Review and Lexapro Label ).

6321677-X | Guillain-barre Syndrome
Adverse event was reported on Aug 12, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: ) was diagnosed with aspergillosis and. Location: NETHERLANDS , 30 years of age, After Noxafil was administered, patient had the following side effects: guillain-barre syndrome (What is guillain-barre syndrome?). During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6313076-1 | No Therapeutic Response
on Aug 10, 2009 Male patient from UNITED STATES , 31 years of age, was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: no therapeutic response. Noxafil dosage: 200 Mg; Qid; Po.

6310872-1 | Guillain-barre Syndrome
on Aug 05, 2009 Male patient from NETHERLANDS , 30 years of age, was diagnosed with aspergillosis and was treated with Noxafil (View Usage). Patient had the following side effects: guillain-barre syndrome (What is guillain-barre syndrome?). Noxafil dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6308378-9 | Guillain-barre Syndrome
Patient was taking Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: guillain-barre syndrome (What is guillain-barre syndrome?) on Jul 31, 2009 from NETHERLANDS Additional patient health information: Male patient , 20 years of age, was diagnosed with bronchopulmonary aspergillosis and. Noxafil dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6300184-4 | Hypoacusis, Tinnitus, Wheezing
Adverse event was reported on Jul 29, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: Po) was diagnosed with bronchopulmonary aspergillosis, pseudomonas infection and. Location: UNITED STATES , 26 years of age, Patient experienced the following unwanted or unexpected effects: hypoacusis, tinnitus (What is tinnitus?), wheezing. During the same period patient was treated with AMBISOME (Iv) (View Ambisome Review and Ambisome Label ), IBUPROFENE (IBUPROFEN) (400 Mg;tid; Po) (View Ibuprofene (ibuprofen) Review and Ibuprofene (ibuprofen) Label ), TOBRAMYCIN SULFATE (Iv) (View Tobramycin Sulfate Review and Tobramycin Sulfate Label ).

6293727-0 | Areflexia, Atrophy, Muscular Weakness, Peripheral Motor Neuropathy
on Jul 27, 2009 Male patient from NETHERLANDS , 20 years of age, was diagnosed with aspergillosis and was treated with Noxafil (View Usage). Patient had the following side effects: areflexia, atrophy, muscular weakness, peripheral motor neuropathy. Noxafil dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6287464-6 | Hypoacusis, Tinnitus, Wheezing
on Jul 22, 2009 Male patient from FRANCE , 26 years of age, was diagnosed with aspergillosis, pseudomonas infection and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: hypoacusis, tinnitus (What is tinnitus?), wheezing. Noxafil dosage: Po. During the same period patient was treated with AMBISOME (Iv) (View Ambisome Review and Ambisome Label ), IBUPROFENE (IBUPROFEN) (400 Mg;tid;po) (View Ibuprofene (ibuprofen) Review and Ibuprofene (ibuprofen) Label ), TOBRAMYCIN SULFATE (Iv) (View Tobramycin Sulfate Review and Tobramycin Sulfate Label ).

6287461-0 | Agitation, Hypertriglyceridaemia
Patient was taking Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, hypertriglyceridaemia on Jul 20, 2009 from FRANCE Additional patient health information: Female patient , 15 years of age, weighting 127.9 lb, was diagnosed with antifungal prophylaxis, metrorrhagia, agitation, prophylaxis against transplant rejection and. Noxafil dosage: 200 Mg;tid;po; 200 Mg;tid. During the same period patient was treated with LUTENYL (NOMEGESTROL ACETATE) (2 Df; Qd; Po) (View Lutenyl (nomegestrol Acetate) Review and Lutenyl (nomegestrol Acetate) Label ), RIVOTRIL (CLONAZEPAM) (4 Mg; Qd; Po) (View Rivotril (clonazepam) Review and Rivotril (clonazepam) Label ), CYCLOSPORINE (40 Mg;bid;po) (View Cyclosporine Review and Cyclosporine Label ), RISPERDAL (View Risperdal Review and Risperdal Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), FUNGIZONE (View Fungizone Review and Fungizone Label ), POLARAMINE (DEXBROMPHENIRAMINE MALEATE) (View Polaramine (dexbrompheniramine Maleate) Review and Polaramine (dexbrompheniramine Maleate) Label ).

6285417-5 | Hypoacusis, Tinnitus
Adverse event was reported on Jul 16, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: Po) was diagnosed with pseudomonas infection, aspergillosis and. Location: FRANCE , 26 years of age, Patient had the following side effects: hypoacusis, tinnitus (What is tinnitus?). During the same period patient was treated with AMBISOME (Iv) (View Ambisome Review and Ambisome Label ), IBUPROFENE (IBUPROFEN) (400 Mg;tid;po) (View Ibuprofene (ibuprofen) Review and Ibuprofene (ibuprofen) Label ), TOBRAMYCIN SULFATE (Iv) (View Tobramycin Sulfate Review and Tobramycin Sulfate Label ).

6284342-3 | Encephalitis, Encephalitis Viral, Encephalopathy, Liver Function Test Abnormal
on Jul 15, 2009 Female patient from UNITED KINGDOM , 42 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: encephalitis (What is encephalitis?), encephalitis viral, encephalopathy, liver function test abnormal. Noxafil dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6284332-0 | Acute Pulmonary Oedema, Atrial Fibrillation, Cardiac Failure, Cardiotoxicity, Congestive Cardiomyopathy, Graft Versus Host Disease, Non-obstructive Cardiomyopathy
on Jul 20, 2009 Female patient from FRANCE , 58 years of age, was diagnosed with antifungal prophylaxis, t-cell lymphoma and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), cardiac failure, cardiotoxicity, congestive cardiomyopathy, graft versus host disease, non-obstructive cardiomyopathy. Noxafil dosage: 200 Mg;tid;po. During the same period patient was treated with DOXORUBICIN HCL (450 Mg/m2; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), NEORAL (View Neoral Review and Neoral Label ), ZELITREX (View Zelitrex Review and Zelitrex Label ), DIFFU K (View Diffu K Review and Diffu K Label ), NEXIUM (View Nexium Review and Nexium Label ), SPECIAFOLDINE (View Speciafoldine Review and Speciafoldine Label ), MAGNE B6 (View Magne B6 Review and Magne B6 Label ). Patient was hospitalized.

6264495-3 | Cardiac Arrest, Presyncope
Patient was taking Noxafil (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), presyncope on Jul 03, 2009 from FRANCE Additional patient health information: Female patient , 45 years of age, . Noxafil dosage: .

6258126-6 | Hypertriglyceridaemia
Adverse event was reported on Jun 23, 2009 by a Female patient taking Noxafil (View Usage) (Dosage: Po) was diagnosed with antifungal prophylaxis and. Location: FRANCE , 18 years of age, After Noxafil was administered, patient had the following side effects: hypertriglyceridaemia. During the same period patient was treated with LUTENYL (NOMEGESTROL ACETATE) (View Lutenyl (nomegestrol Acetate) Review and Lutenyl (nomegestrol Acetate) Label ), RIVOTRIL (CLONAZEPAM) (View Rivotril (clonazepam) Review and Rivotril (clonazepam) Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6258125-4 | Leukopenia, Neutropenia
on Jun 29, 2009 Female patient from FRANCE , 58 years of age, was diagnosed with aspergillosis and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: leukopenia, neutropenia. Noxafil dosage: 200 Mg; Qid; Po. During the same period patient was treated with CANCIDAS (View Cancidas Review and Cancidas Label ), TAVANIC (View Tavanic Review and Tavanic Label ). Patient was hospitalized.

6255557-5 | Acute Pulmonary Oedema, Atrial Fibrillation, Cardiac Failure Congestive, Cardiotoxicity, Congestive Cardiomyopathy, Graft Versus Host Disease
on Jun 29, 2009 Female patient from FRANCE , 58 years of age, was diagnosed with prophylaxis, t-cell lymphoma and was treated with Noxafil (View Usage). Patient had the following side effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), cardiac failure congestive, cardiotoxicity, congestive cardiomyopathy, graft versus host disease. Noxafil dosage: 200 Mg;tid; Po. During the same period patient was treated with DOXORUBICIN HCL (450 Mg/m2; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), NEORAL (View Neoral Review and Neoral Label ), ZELITREX (View Zelitrex Review and Zelitrex Label ), DIFFU K (View Diffu K Review and Diffu K Label ), NEXIUM (View Nexium Review and Nexium Label ), SPECIAFOLDINE (View Speciafoldine Review and Speciafoldine Label ), MAGNE B6 (View Magne B6 Review and Magne B6 Label ). Patient was hospitalized.

6249839-0 | Atrial Fibrillation, Cardiac Failure Congestive, Cardiotoxicity
Patient was taking Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), cardiac failure congestive, cardiotoxicity on Jun 22, 2009 from FRANCE Additional patient health information: Female patient , 58 years of age, was diagnosed with antifungal prophylaxis, t-cell lymphoma and. Noxafil dosage: 200 Mg; Tid; Po. During the same period patient was treated with DOXORUBICIN HCL (450 Mg/m2; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), NEORAL (View Neoral Review and Neoral Label ), ZELITREX (View Zelitrex Review and Zelitrex Label ), DIFFU K (View Diffu K Review and Diffu K Label ), NEXIUM (View Nexium Review and Nexium Label ), SPECIAFOLDINE (View Speciafoldine Review and Speciafoldine Label ), MAGNE B6 (View Magne B6 Review and Magne B6 Label ). Patient was hospitalized.

6235340-7 | Acute Pulmonary Oedema, Atrial Fibrillation, Cardiac Failure Congestive, Cardiotoxicity
Adverse event was reported on Jun 10, 2009 by a Female patient taking Noxafil (View Usage) (Dosage: 200 Mg; Tid; Po) was diagnosed with t-cell lymphoma and. Location: FRANCE , 58 years of age, Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), cardiac failure congestive, cardiotoxicity. During the same period patient was treated with DOXORUBICINE (DOXORUBICINE HYDROCHLORIDE) (450 Mg/m2; Iv) (View Doxorubicine (doxorubicine Hydrochloride) Review and Doxorubicine (doxorubicine Hydrochloride) Label ), NEORAL (CON.) (View Neoral (con.) Review and Neoral (con.) Label ), ZELITREX (CON.) (View Zelitrex (con.) Review and Zelitrex (con.) Label ), DIFFU K (CON.) (View Diffu K (con.) Review and Diffu K (con.) Label ), INEXIUM (CON.) (View Inexium (con.) Review and Inexium (con.) Label ), SPECIAFOLDINE (CON.) (View Speciafoldine (con.) Review and Speciafoldine (con.) Label ), MAGNE B6 (CON.)C (View Magne B6 (con.)c Review and Magne B6 (con.)c Label ). Patient was hospitalized.

6230672-0 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Arthropathy, Colitis, Cytomegalovirus Infection, Gastrointestinal Haemorrhage, Ileitis
on Jun 06, 2009 Male patient from CHILE , 39 years of age, was diagnosed with fusarium infection and was treated with Noxafil (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, arthropathy, colitis, cytomegalovirus infection (What is cytomegalovirus infection?), gastrointestinal haemorrhage, ileitis. Noxafil dosage: 200 Mg;tid;. During the same period patient was treated with VORICONAZOLE (VORICONAZOLE) (View Voriconazole (voriconazole) Review and Voriconazole (voriconazole) Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), DACLIZUMAB (CON.) (View Daclizumab (con.) Review and Daclizumab (con.) Label ), CICLOSPORINE (CON.) (View Ciclosporine (con.) Review and Ciclosporine (con.) Label ), CORTICOSTEROIDS (CON.) (View Corticosteroids (con.) Review and Corticosteroids (con.) Label ), SULFASALAZINE (CON.) (View Sulfasalazine (con.) Review and Sulfasalazine (con.) Label ), VANCOMYCINE (CON.) (View Vancomycine (con.) Review and Vancomycine (con.) Label ), MEROPENEM (CON.) (View Meropenem (con.) Review and Meropenem (con.) Label ). Patient was hospitalized.

6221427-1 | Aplasia Pure Red Cell
on Jun 03, 2009 Female patient from BELGIUM , 58 years of age, weighting 149.9 lb, was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: aplasia pure red cell. Noxafil dosage: 2.5 Ml; Po. During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6221348-4 | Blood Alkaline Phosphatase Increased, Condition Aggravated, Ileus, Leukaemia, Malignant Neoplasm Progression, Nausea, Pain
Patient was taking Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase increased, condition aggravated, ileus, leukaemia, malignant neoplasm progression, nausea (What is nausea?), pain (What is pain?) on Jun 03, 2009 from CHILE Additional patient health information: Male patient , child 12 years of age, weighting 83.78 lb, was diagnosed with fungal infection (What is fungal infection?), leukaemia and. Noxafil dosage: 200 Mg; Qid; Po, 400 Mg; Bid; Po. During the same period patient was treated with VINCRISTINE (; Qw;) (View Vincristine Review and Vincristine Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), LEVETIRACETAM (View Levetiracetam Review and Levetiracetam Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), KETOPROFEN (View Ketoprofen Review and Ketoprofen Label ).

6221347-2 | Acute Graft Versus Host Disease In Skin, Arthropathy, Blood Culture Positive, Cytomegalovirus Infection, Enterocolitis, Fusarium Infection, Gastrointestinal Haemorrhage, Muscle Disorder
Adverse event was reported on Jun 04, 2009 by a Male patient taking Noxafil (View Usage) (Dosage: ) was diagnosed with fusarium infection and. Location: CHILE , 39 years of age, Patient had the following side effects: acute graft versus host disease in skin, arthropathy, blood culture positive, cytomegalovirus infection (What is cytomegalovirus infection?), enterocolitis, fusarium infection, gastrointestinal haemorrhage, muscle disorder (What is muscle disorder?). During the same period patient was treated with VORICONAZOLE (VORICONAZOLE) (View Voriconazole (voriconazole) Review and Voriconazole (voriconazole) Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), DACLIZUMAB (View Daclizumab Review and Daclizumab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), VANCOMYCINE (View Vancomycine Review and Vancomycine Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), REMICADE (View Remicade Review and Remicade Label ). Patient was hospitalized.

6217040-2 | Acute Graft Versus Host Disease In Skin, Enterocolitis, Fusarium Infection, Gastrointestinal Haemorrhage, Pathogen Resistance, Pseudomonal Bacteraemia, Sepsis
on May 29, 2009 Male patient from CHILE , 39 years of age, was diagnosed with fusarium infection and was treated with Noxafil (View Usage). After Noxafil was administered, patient had the following side effects: acute graft versus host disease in skin, enterocolitis, fusarium infection, gastrointestinal haemorrhage, pathogen resistance, pseudomonal bacteraemia, sepsis (What is sepsis?). Noxafil dosage: . During the same period patient was treated with VORICONAZOLE (VORICONAZOLE) (View Voriconazole (voriconazole) Review and Voriconazole (voriconazole) Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), DACLIZUMAB (View Daclizumab Review and Daclizumab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), SULFASALAZINE (View Sulfasalazine Review and Sulfasalazine Label ), VANCOMYCINE (View Vancomycine Review and Vancomycine Label ), MEROPENEM (View Meropenem Review and Meropenem Label ). Patient was hospitalized.

6215778-4 | Pseudomonas Infection, Therapeutic Response Unexpected, Transplant
on May 28, 2009 Male patient from CHILE , 13 years of age, weighting 59.52 lb, was diagnosed with fungal infection (What is fungal infection?), off label use and was treated with Noxafil (View Usage). Patient experienced the following unwanted or unexpected effects: pseudomonas infection, therapeutic response unexpected, transplant. Noxafil dosage: 200 Mg; Tid; Po. During the same period patient was treated with CASPOFUNGIN (View Caspofungin Review and Caspofungin Label ), VORICONAZOL (View Voriconazol Review and Voriconazol Label ), VANCOMYCINE (View Vancomycine Review and Vancomycine Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ), LYRICA (View Lyrica Review and Lyrica Label ).

6194946-4 | Bradycardia, Cardiac Disorder, Hypokalaemia
Patient was taking Noxafil (View Usage). Patient had the following side effects: bradycardia, cardiac disorder, hypokalaemia on May 07, 2009 from GREECE Additional patient health information: Female patient , 30 years of age, was diagnosed with antifungal treatment and. Noxafil dosage: . During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ). Patient was hospitalized.